Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Chebi:72305
2. Teduglutide (rdna Origin)
3. Chembl2104987
4. Bdbm50183895
| Molecular Weight | 3752.1 g/mol |
|---|---|
| Molecular Formula | C164H252N44O55S |
| XLogP3 | -15.2 |
| Hydrogen Bond Donor Count | 55 |
| Hydrogen Bond Acceptor Count | 60 |
| Rotatable Bond Count | 126 |
| Exact Mass | 3750.8028943 g/mol |
| Monoisotopic Mass | 3749.7995395 g/mol |
| Topological Polar Surface Area | 1650 Ų |
| Heavy Atom Count | 264 |
| Formal Charge | 0 |
| Complexity | 9030 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 38 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Teduglutide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Short Bowel Syndrome.
Lead Product(s): Teduglutide,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 15, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Teduglutide,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome
Details : Teduglutide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Short Bowel Syndrome.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
May 15, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Under the collaboration, OPKO will supply its proprietary long-acting GLP-2 peptide and certain Oxyntomodulin analogs, including Teduglutide, the only approved GLP-2 analog, for the development of oral tablet formulations using Entera’s proprietary oral delivery technology.
Lead Product(s): Teduglutide,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Peptide, Unconjugated
Sponsor: OPKO Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 12, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Teduglutide,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : OPKO Biologics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, OPKO will supply its proprietary long-acting GLP-2 peptide and certain Oxyntomodulin analogs, including Teduglutide, the only approved GLP-2 analog, for the development of oral tablet formulations using Entera’s proprietary ora...
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
September 12, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Teduglutide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Short Bowel Syndrome.
Lead Product(s): Teduglutide,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 30, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Teduglutide,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older
Details : Teduglutide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Short Bowel Syndrome.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
August 30, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Teduglutide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Teduglutide,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Peptide, Unconjugated
Sponsor: Takeda Pharmaceutical
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 10, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Teduglutide,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Teduglutide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
July 10, 2020

Details:
Teduglutide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Lead Product(s): Teduglutide,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: SHIRE PLC
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 16, 2019

Lead Product(s) : Teduglutide,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : SHIRE PLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Teduglutide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
May 16, 2019

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Teduglutide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Short Bowel Syndrome.
Lead Product(s): Teduglutide,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 10, 2018

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Teduglutide,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Teduglutide in Japanese Participants With Short Bowel Syndrome
Details : Teduglutide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Short Bowel Syndrome.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
September 10, 2018

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Teduglutide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Short Bowel Syndrome.
Lead Product(s): Teduglutide,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 23, 2018

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Teduglutide,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Teduglutide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Short Bowel Syndrome.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
July 23, 2018

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Teduglutide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Short Bowel Syndrome.
Lead Product(s): Teduglutide,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 27, 2018

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Teduglutide,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Teduglutide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Short Bowel Syndrome.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
June 27, 2018

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Teduglutide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Short Bowel Syndrome.
Lead Product(s): Teduglutide,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Takeda Pharmaceutical
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 31, 2017

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Teduglutide,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302
Details : Teduglutide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Short Bowel Syndrome.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
August 31, 2017

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Teduglutide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Short Bowel Syndrome.
Lead Product(s): Teduglutide,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 02, 2016

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Teduglutide,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Teduglutide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Short Bowel Syndrome.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
December 02, 2016

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2025-11-01
US Patent Number : 9060992
Drug Substance Claim :
Drug Product Claim :
Application Number : 203441
Patent Use Code : U-1320
Delist Requested : Y
Patent Use Description : TREATMENT OF ADULT PAT...
Patent Expiration Date : 2025-11-01

Patent Expiration Date : 2025-11-01
US Patent Number : 7847061
Drug Substance Claim :
Drug Product Claim :
Application Number : 203441
Patent Use Code : U-1320
Delist Requested : Y
Patent Use Description : TREATMENT OF ADULT PAT...
Patent Expiration Date : 2025-11-01

Patent Expiration Date : 2026-05-01
US Patent Number : 7847061*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 203441
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-05-01

Patent Expiration Date : 2026-05-01
US Patent Number : 9060992*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 203441
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-05-01

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : ODE-240
Exclusivity Expiration Date : 2026-05-16
Application Number : 203441
Product Number : 1
Exclusivity Details :

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
78
PharmaCompass offers a list of Teduglutide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Teduglutide manufacturer or Teduglutide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Teduglutide manufacturer or Teduglutide supplier.
PharmaCompass also assists you with knowing the Teduglutide API Price utilized in the formulation of products. Teduglutide API Price is not always fixed or binding as the Teduglutide Price is obtained through a variety of data sources. The Teduglutide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A GATTEX KIT manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of GATTEX KIT, including repackagers and relabelers. The FDA regulates GATTEX KIT manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. GATTEX KIT API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of GATTEX KIT manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A GATTEX KIT supplier is an individual or a company that provides GATTEX KIT active pharmaceutical ingredient (API) or GATTEX KIT finished formulations upon request. The GATTEX KIT suppliers may include GATTEX KIT API manufacturers, exporters, distributors and traders.
click here to find a list of GATTEX KIT suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A GATTEX KIT DMF (Drug Master File) is a document detailing the whole manufacturing process of GATTEX KIT active pharmaceutical ingredient (API) in detail. Different forms of GATTEX KIT DMFs exist exist since differing nations have different regulations, such as GATTEX KIT USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A GATTEX KIT DMF submitted to regulatory agencies in the US is known as a USDMF. GATTEX KIT USDMF includes data on GATTEX KIT's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The GATTEX KIT USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of GATTEX KIT suppliers with USDMF on PharmaCompass.
A GATTEX KIT written confirmation (GATTEX KIT WC) is an official document issued by a regulatory agency to a GATTEX KIT manufacturer, verifying that the manufacturing facility of a GATTEX KIT active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting GATTEX KIT APIs or GATTEX KIT finished pharmaceutical products to another nation, regulatory agencies frequently require a GATTEX KIT WC (written confirmation) as part of the regulatory process.
click here to find a list of GATTEX KIT suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing GATTEX KIT as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for GATTEX KIT API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture GATTEX KIT as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain GATTEX KIT and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a GATTEX KIT NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of GATTEX KIT suppliers with NDC on PharmaCompass.
GATTEX KIT Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of GATTEX KIT GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right GATTEX KIT GMP manufacturer or GATTEX KIT GMP API supplier for your needs.
A GATTEX KIT CoA (Certificate of Analysis) is a formal document that attests to GATTEX KIT's compliance with GATTEX KIT specifications and serves as a tool for batch-level quality control.
GATTEX KIT CoA mostly includes findings from lab analyses of a specific batch. For each GATTEX KIT CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
GATTEX KIT may be tested according to a variety of international standards, such as European Pharmacopoeia (GATTEX KIT EP), GATTEX KIT JP (Japanese Pharmacopeia) and the US Pharmacopoeia (GATTEX KIT USP).